Summary
Regeneron Pharmaceuticals, Inc. has entered into a significant agreement with Genentech, Inc., to settle patent litigation and secure a non-exclusive license for its flagship eye drug, EYLEA™ (aflibercept), specifically for its use in the United States for treating human eye diseases. This agreement, effective December 31, 2011, resolves a dispute over the Davis-Smyth patents, which are crucial for EYLEA's ophthalmic application. From an investor's perspective, this settlement is a critical step in de-risking EYLEA's U.S. commercialization. While the company will incur future payments based on EYLEA's U.S. sales, the resolution removes a major legal overhang. The financial terms include a $60 million lump-sum payment triggered by $400 million in cumulative U.S. sales, followed by tiered royalty payments (4.75% and 5.5%) on sales exceeding $400 million up to $3 billion and above $3 billion, respectively, until May 7, 2016. This structure aligns future payments with EYLEA's commercial success.
Key Highlights
- 1Regeneron has settled patent litigation with Genentech concerning EYLEA's U.S. ophthalmic use via a non-exclusive license and partial settlement agreement.
- 2The agreement grants Regeneron a license to specific Genentech patents, including the disputed Davis-Smyth patents, essential for EYLEA's treatment of human eye diseases in the U.S.
- 3The resolution removes a significant legal impediment to EYLEA's market penetration and commercial success in the United States.
- 4Future payments to Genentech are contingent on EYLEA's U.S. sales performance, structured as a $60 million lump sum upon reaching $400 million in cumulative sales.
- 5Tiered royalties will be paid on cumulative U.S. EYLEA sales exceeding $400 million: 4.75% on sales between $400 million and $3 billion, and 5.5% on sales over $3 billion, until May 7, 2016.
- 6The agreement does not cover EYLEA's use outside the U.S. or other applications of aflibercept; patent litigation continues for matters not covered by this settlement.